

09/ 422/107

(FILE 'HOME' ENTERED AT 08:32:13 ON 11 AUG 2003)

FILE 'REGISTRY' ENTERED AT 08:32:31 ON 11 AUG 2003

L1 212 S ST[ASCT]VL[GEN] [RK] L[STAT] [NQ] EL. [RK] LQTYPRTN[TV] GS [NG] T[YP] /
L2 54 S L1 AND 20-30/SQL

FILE 'CAPLUS' ENTERED AT 08:34:36 ON 11 AUG 2003

L3 12 S L2

FILE 'REGISTRY' ENTERED AT 08:42:14 ON 11 AUG 2003

L4 210 S ST[ASCT]VL[GEN] [RK] L[STAT] [NQ] EL[HILV] [RK] LQTYPRTN[TV] GS [NG] T
L5 54 S L4 AND 20-30/SQL

FILE 'CAPLUS' ENTERED AT 08:44:02 ON 11 AUG 2003

L6 12 S L5
L7 1 S L6 AND (AMYLIN?)
L8 2 S L6 AND DIABETE?
L9 1 S L8 NOT L7
L10 133 S 1 HIT

FILE 'REGISTRY' ENTERED AT 08:51:22 ON 11 AUG 2003

L11 3 S (108470-28-6 OR 108569-11-5 OR 108470-29-7)/RN

FILE 'REGISTRY' ENTERED AT 08:54:18 ON 11 AUG 2003

L12 210 S ST[ASCT]VL[GEN] [RK] L[STAT] [NQ] EL[HILV] [RK] LQTYPRTN[TV] GS [NG] T
L13 0 S CST[ASCT]VL[GEN] [RK] L[STAT] [NQ] EL[HILV] [RK] LQTYPRTN[TV] GS [NG]
L14 210 S L12 NOT L13
L15 3 S CLST[ASCT]VL[GEN] [RK] L[STAT] [NQ] EL[HILV] [RK] LQTYPRTN[TV] GS [NG]
L16 207 S L12 NOT L15

FILE 'CAPLUS' ENTERED AT 08:56:35 ON 11 AUG 2003

L17 1236 S L16

FILE 'REGISTRY' ENTERED AT 08:56:55 ON 11 AUG 2003

L18 207 S L12 NOT L15
L19 51 S L18 AND 20-30/SQL

FILE 'CAPLUS' ENTERED AT 08:57:17 ON 11 AUG 2003

L20 9 S L19

=>

L3 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
 1997:272955 Document No. 126:338955 Structure/function relationships of calcitonin analogs as agonists, antagonists, or inverse agonists in a constitutively activated receptor cell system. Pozvek, Gordana; Hilton, Joanne M.; Quiza, Maribel; Houssami, Souheir; Sexton, Patrick M. (Neurobiology Unit, St. Vincent's Institute of Medical Research, Victoria, 3065, Australia). Molecular Pharmacology, 51(4), 658-665 (English) 1997. CODEN: MOPMA3. ISSN: 0026-895X. Publisher: Williams & Wilkins.

IT **189951-67-5**, SDZ 218-686
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (structure/function relationships of calcitonin analogs as agonists, antagonists, or inverse agonists in a constitutively activated receptor cell system)

L3 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
 1995:11657 Document No. 122:81967 Synthesis of [4,5-3H-Leu4]salmon calcitonin. Birtle, T.; White, A. J.; Woodhouse, D. P. (Cambridge Res. Biochem., Zeneca Spec., Billingham/Cleveland, TS23 1YN, UK). Journal of Labelled Compounds and Radiopharmaceuticals, 34(4), 401-10 (English) 1994. CODEN: JLCRD4. ISSN: 0362-4803.

IT **160275-15-0DP**, Pepsyn KAM-bound
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as intermediate in synthesis of tritium-labeled leucine calcitonin)

L3 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
 1992:626460 Document No. 117:226460 N-terminal truncation of salmon calcitonin leads to calcitonin antagonists. Feyen, Jean H. M.; Cardinaux, Francis; Gamse, Rainer; Bruns, Christian; Azria, Moise; Trechsel, Ulrich (Preclin. Res., SANDOZ PHARMA Ltd., Basel, CH-4002, Switz.). Biochemical and Biophysical Research Communications, 187(1), 8-13 (English) 1992. CODEN: BBRCA9. ISSN: 0006-291X.

IT **110917-40-3 110917-52-7 144500-18-5**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (biol. activity of, structure in relation to)

L3 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
 1991:214432 Document No. 114:214432 Therapeutic aerosol spray formulations comprising drug complexes with extenders. Felt, George Robert; Warchol, Mark Peter (Rorer International (Overseas), Inc., USA). PCT Int. Appl. WO 9009781 A1 19900907, 57 pp. DESIGNATED STATES: W: AU, BR, CA, FI, JP, NO; RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1990-US928 19900221. PRIORITY: US 1989-314605 19890223.

IT **108470-28-6D**, complexes with extenders
 RL: PROC (Process)
 (aerosol formulation of)

L3 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
 1991:12192 Document No. 114:12192 Intranasal calcitonin formulations. Klunk, Lewis J., Jr.; Grebow, Peter E.; Li, Herschel H. (Rorer International (Overseas), Inc., USA). Eur. Pat. Appl. EP 358234 A2 19900314, 22 pp. DESIGNATED STATES: R: DE, ES, FR, GB, IT. (English). CODEN: EPXXDW. APPLICATION: EP 1989-116685 19890908. PRIORITY: US 1988-242000 19880908.

IT **108470-29-7**
 RL: BIOL (Biological study)
 (intranasal compn. of, aminolevulinate as stabilizer in)

L3 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
 1990:217544 Document No. 112:217544 Preparation of calcitonin and LH-RH

antagonist peptides modified by sugar molecules or polyhydroxy compounds.
Albert, Rainer; Bauer, Wilfried; Cardinaux, Francois; Pless, Janos
(Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.; Sandoz A.-G.). PCT Int. Appl. WO
8909786 A1 19891019, 82 pp. DESIGNATED STATES: W: AT, AU, CH, DE, JP,
KR. (English). CODEN: PIXXD2. APPLICATION: WO 1989-EP373 19890407.
PRIORITY: GB 1988-8275 19880408; GB 1988-8528 19880412.

IT 110917-25-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(prepn. and reaction of, in prepn. of hypocalcemic and LHRH antagonist)

IT 127010-49-5P 127010-51-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as hypocalcemic and LHRH antagonist)

L3 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN

1989:213349 Document No. 110:213349 Preparation of glycosylated bioactive
peptide drugs with prolonged duration of action. (Sandoz-Erfindungen
Verwaltungsgesellschaft m.b.H., Austria; Sandoz A.-G.;
Sandoz-Patent-G.m.b.H.). PCT Int. Appl. WO 8802756 A2 19880421, 147 pp.
DESIGNATED STATES: W: AT, CH, DE. (English). CODEN: PIXXD2.
APPLICATION: WO 1987-EP593 19871012. PRIORITY: DE 1986-3634797 19861013;
DE 1986-3634826 19861013; DE 1986-3634825 19861013; DE 1987-3712626
19870414; CH 1987-3153 19870817.

IT 111056-98-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(prepn. and acylation of, by quinic acid)

IT 119643-72-0P 119643-73-1P 119643-74-2P

119643-75-3P 119662-42-9P 119662-43-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)

(prepn. of, as drug)

IT 110917-78-7P 119643-11-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as drug intermediate)

IT 119683-15-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in prepn. of drug)

L3 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN

1987:598934 Document No. 107:198934 Preparation of calcitonin analogs for
treatment of osteoporosis and hypocalcemia. Cardinaux, Francois; Pless,
Janos; Buck, Robert Helmut (Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.). Ger.
Offen. DE 3640042 A1 19870611, 13 pp. (German). CODEN: GWXXBX.
APPLICATION: DE 1986-3640042 19861124. PRIORITY: DE 1985-3542859
19851204; DE 1986-3614784 19860502.

IT 110734-10-6P 110917-67-4P 110917-71-0P

110917-78-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(prepn. and deprotection of, in synthesis of calcitonin analog)

IT 110917-69-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(prepn. and peptide coupling of, in synthesis of calcitonin analog)

IT 110917-25-4P 110917-26-5P 110917-27-6P

110917-30-1P 110917-36-7P 110917-39-0P

110917-40-3P 110917-42-5P 110917-43-6P

110917-47-0P 110917-48-1P 110917-51-6P

110917-52-7P 110917-53-8P 110917-54-9P

110917-55-0P 110917-56-1P 110917-57-2P

110917-59-4P 110917-60-7P 110945-70-5P

110945-74-9P 111056-98-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as calcitonin analog for treatment of osteoporosis and hypocalcemia)

L3 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN

1987:407614 Document No. 107:7614 Des-2-serine, 3 asparagine-calcitonin.
Orlowski, Ronald C.; Seyler, Jay K. (Armour Pharmaceutical Co., USA).
U.S. US 4622388 A 19861111, 10 pp. (English). CODEN: USXXAM.
APPLICATION: US 1985-797074 19851112.

IT **108470-28-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. and cyclization of)

IT **108569-11-5DP**, benzydrylamine resin-bound

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and deprotection and resin cleavage of)

IT **108470-29-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for removal of calcium from blood)

=>

(FILE 'HOME' ENTERED AT 08:32:13 ON 11 AUG 2003)

FILE 'REGISTRY' ENTERED AT 08:32:31 ON 11 AUG 2003

L1 212 S ST[ASCT]VL[GEN] [RK]L[STAT] [NQ]EL. [RK]LQTYPRTN[TV]GS[NG]T[YP] /
L2 54 S L1 AND 20-30/SQL

FILE 'CAPLUS' ENTERED AT 08:34:36 ON 11 AUG 2003

L3 12 S L2

FILE 'REGISTRY' ENTERED AT 08:42:14 ON 11 AUG 2003

L4 210 S ST[ASCT]VL[GEN] [RK]L[STAT] [NQ]EL[HILV] [RK]LQTYPRTN[TV]GS[NG]T
L5 54 S L4 AND 20-30/SQL

FILE 'CAPLUS' ENTERED AT 08:44:02 ON 11 AUG 2003

L6 12 S L5
L7 1 S L6 AND (AMYLIN?)
L8 2 S L6 AND DIABETE?
L9 1 S L8 NOT L7
L10 133 S 1 HIT

=>

L11 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2003 ACS on STN
RN 108569-11-5 REGISTRY

SEQ3 1 Cys-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L11 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2003 ACS on STN
RN 108470-29-7 REGISTRY

SEQ3 1 Cys-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L11 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2003 ACS on STN
RN 108470-28-6 REGISTRY

SEQ3 1 Cys-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

09/22/04

(FILE 'HOME' ENTERED AT 08:17:30 ON 11 AUG 2003)

FILE 'REGISTRY' ENTERED AT 08:17:41 ON 11 AUG 2003

L1 304 S [LT]..L[STAT] [NQ]EL. [RK] LQTYPRTN[TV]GS [NG]T[YP]/SQSP
L2 0 S L1 AND 20-40
L3 288 S L1 AND 20-40/SQL

FILE 'CAPLUS' ENTERED AT 08:18:45 ON 11 AUG 2003

L4 1265 S L3

FILE 'REGISTRY' ENTERED AT 08:19:02 ON 11 AUG 2003

L5 286 S [LT] [GEN] [RK] L[STAT] [NQ]EL. [RK] LQTYPRTN[TV]GS [NG]T[YP]/SQSP
L6 93 S L5 AND 20-30/SQL

FILE 'CAPLUS' ENTERED AT 08:19:46 ON 11 AUG 2003

L7 38 S L6

FILE 'REGISTRY' ENTERED AT 08:23:31 ON 11 AUG 2003

L8 8 S (144500-19-6 OR 144500-20-9 OR 151804-54-5 OR 151804-59-0 OR

=>

L7 ANSWER 27 OF 38 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:31230 CAPLUS
 DN 120:31230
 TI Preparation of novel amylin antagonist peptides and uses thereof
 IN Gaeta, Laura S. L.; Jones, Howard; Albrecht, Elisabeth; Prickett, Kathryn;
 Beaumont, Kevin
 PA Amylin Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9310147	A1	19930527	WO 1992-US10011	19921119
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	US 5580953	A	19961203	US 1991-794288	19911119
	AU 9331431	A1	19930615	AU 1993-31431	19921119
	AU 672589	B2	19961010		
	JP 06504795	T2	19940602	JP 1992-509532	19921119
	NO 9302604	A	19930917	NO 1993-2604	19930719
PRAI	US 1991-794288	A	19911119		
	US 1991-744586	B2	19910814		
	WO 1992-US10011	A	19921119		

AB Amylin antagonists comprising N-terminal deletion peptides of Peptide A, modified Peptide A, Peptide B, modified Peptide B, Peptide C, or modified Peptide C, wherein at least the first two to seven N-terminal amino acid residues of Peptide A or modified Peptide A have been deleted, at least the first eight N-terminal amino acid residues of Peptide B or modified Peptide B have been deleted, and at least the first two to seven N-terminal amino acid residues of Peptide C or modified Peptide C have been deleted, each such amylin antagonist compd. optionally having an acetylated N-terminal amino acid, and amidated C-terminal amino acid, or both, were prepd. Thus, 18-32-Peptide C was prepd. using 4-methylbenzhydrylamine resin and BOC-protected amino acids. Title compds. having IC₅₀'s of <5 nM and <1 .mu.M in an amylin receptor assay and a soleus muscle antagonist assay, resp., are claimed.

IT 144500-19-6P 144500-20-9P 151804-54-5P
 151804-59-0P 151804-77-2P 151804-79-4P
 151804-85-2P 155069-90-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as amylin antagonist)

=>

L8 ANSWER 1 OF 8 REGISTRY COPYRIGHT 2003 ACS on STN
RN 155069-90-2 REGISTRY

SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
11 Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
21 Gly-Ser-Gly-Thr-Pro

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2003 ACS on STN
RN 151804-85-2 REGISTRY

SEQ3 1 Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Arg-
11 Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-
21 Ser-Asn-Thr-Tyr

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2003 ACS on STN
RN 151804-79-4 REGISTRY

SEQ3 1 Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-
11 Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-
21 Ser-Asn-Thr-Tyr

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2003 ACS on STN
RN 151804-77-2 REGISTRY

SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
11 Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
21 Gly-Ser-Asn-Thr-Tyr

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2003 ACS on STN
RN 151804-59-0 REGISTRY

SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
11 Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
21 Gly-Ser-Asn-Thr-Tyr

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2003 ACS on STN
RN 151804-54-5 REGISTRY

SEQ3 1 Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-
11 Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-
21 Ser-Gly-Thr-Pro

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2003 ACS on STN
RN 144500-20-9 REGISTRY

SEQ3 1 Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-
11 Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-
21 Ser-Gly-Thr-Pro

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L8 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2003 ACS on STN
RN 144500-19-6 REGISTRY

SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
11 Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
21 Gly-Ser-Gly-Thr-Pro

RELATED SEQUENCES AVAILABLE WITH SEQLINK